GlassScriptPhysician profile
Arthur J Mcdermet
NPI 1578542965
$9,927.73
in general payments reported to CMS, 2019-2025
37 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,902 · 2020: $954 · 2021: $625 · 2022: $946 · 2023: $1,689 · 2024: $1,991 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,462.11 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,815.88 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,059.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $915.32 | 2019-2025 | Verquvo, Segluromet, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $689.87 | 2021-2024 | |
| Glaxosmithkline, LLC. | $575.59 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.14 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $500.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $494.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $461.50 | 2019-2023 | |
| Pfizer INC. | $430.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $343.27 | 2019 | |
| Abbott Laboratories | $294.48 | 2019-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $268.66 | 2020-2021 | |
| Amarin Pharma, INC. | $267.71 | 2019-2020 | |
| Abbvie INC. | $183.67 | 2023-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Mcdermet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.